1. Home
  2. EIG vs GERN Comparison

EIG vs GERN Comparison

Compare EIG & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Employers Holdings Inc

EIG

Employers Holdings Inc

N/A

Current Price

$47.67

Market Cap

928.6M

Sector

Finance

ML Signal

N/A

Logo Geron Corporation

GERN

Geron Corporation

N/A

Current Price

$0.99

Market Cap

1.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EIG
GERN
Founded
2000
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
928.6M
1.0B
IPO Year
2006
1996

Fundamental Metrics

Financial Performance
Metric
EIG
GERN
Price
$47.67
$0.99
Analyst Decision
Buy
Buy
Analyst Count
3
5
Target Price
★ $54.00
$3.63
AVG Volume (30 Days)
143.7K
★ 14.6M
Earning Date
10-28-2026
11-04-2026
Dividend Yield
★ 2.88%
N/A
EPS Growth
N/A
★ 51.85
EPS
★ 2.73
N/A
Revenue
★ $858,700,000.00
$1,065,000.00
Revenue This Year
N/A
$27.99
Revenue Next Year
N/A
$44.91
P/E Ratio
$17.35
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$37.44
$0.84
52 Week High
$53.51
$2.01

Technical Indicators

Market Signals
Indicator
EIG
GERN
Relative Strength Index (RSI) 42.59 39.98
Support Level $41.49 $0.84
Resistance Level $51.18 $1.67
Average True Range (ATR) 1.79 0.09
MACD -0.39 -0.00
Stochastic Oscillator 34.41 36.08

Price Performance

Historical Comparison
EIG
GERN

About EIG Employers Holdings Inc

Employers Holdings Inc is a provider of workers' compensation insurance and services focused on small and mid-sized businesses engaged in low-to-medium hazard industries. Its customers are employers, and the insurance premiums that those employers pay to account for company revenue. Substantially all of the remaining revenue is generated through investments. The company operates exclusively in the United States, and it generates more than half of its business in California. By industry, the company has exposure to restaurants, which account for roughly a fourth of the total premiums the company earns. It operates as a single reportable segment, Insurance Operations through its wholly owned subsidiaries.

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Share on Social Networks: